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Abstract
Background: Cerebral small vessel disease is a major cause of dementia and stroke, visible on brain magnetic
resonance imaging. Recent data suggest that small vessel disease lesions may be dynamic, damage extends into
normal-appearing brain and microvascular dysfunctions include abnormal blood–brain barrier leakage, vasoreactivity
and pulsatility, but much remains unknown regarding underlying pathophysiology, symptoms, clinical features and risk
factors of small vessel disease.
Patients and Methods: The Mild Stroke Study 3 is a prospective observational cohort study to identify risk factors for
and clinical implications of small vessel disease progression and regression among up to 300 adults with non-disabling
stroke. We perform detailed serial clinical, cognitive, lifestyle, physiological, retinal and brain magnetic resonance imaging
assessments over one year; we assess cerebrovascular reactivity, blood flow, pulsatility and blood–brain barrier leakage
on magnetic resonance imaging at baseline; we follow up to four years by post and phone. The study is registered
ISRCTN 12113543.
Summary: Factors which influence direction and rate of change of small vessel disease lesions are poorly understood.
We investigate the role of small vessel dysfunction using advanced serial neuroimaging in a deeply phenotyped cohort to
increase understanding of the natural history of small vessel disease, identify those at highest risk of early disease
progression or regression and uncover novel targets for small vessel disease prevention and therapy.
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Cerebral small vessel disease (SVD) describes diffuse
disease processes affecting the perforating cerebral
arterioles, capillaries, venules and consequent damage
to the white and deep grey matter.1 This damage is
visible on brain MRI as white matter hyperintensities
(WMH), recent small subcortical infarcts, perivascular
spaces, brain atrophy and cerebral microbleeds.2
SVD causes 20% of ischaemic strokes and almost
half of all dementias,3,4 contributing to both vascular
and Alzheimer’s dementia subtypes,5 its presence more
than doubling future risk of stroke, dementia and func-
tional impairment.6
Recent advances in neuroimaging have uncovered
candidate mechanisms for underlying pathophysiolog-
ical processes. Furthermore, SVD appears to be more
dynamic and global than previously thought, since
recent studies show: (a) WMH can regress as well as
progress;7–10 (b) SVD is associated with cerebrovascu-
lar dysfunction including diffuse blood–brain barrier
(BBB) failure;11 (c) with some evidence for other vas-
cular dysfunctions including reduced cerebrovascular
reactivity (CVR) and increased intracranial pulsatil-
ity12–14 and (d) acute, apparently ‘silent’, lesions on
diffusion weighted imaging (DWI) may be more fre-
quent than previously thought.15–17
Most SVD lesions are thought to develop ‘silently’.
However, some studies suggest that SVD lesions are
associated with subjective cognitive complaints,18 gait
disturbance,19 mood disorders and apathy.20
Moreover, subtle symptoms have been associated
with acute DWI lesions in a few small cross-sectional
studies in non-stroke populations (n¼ 6/649;
n¼ 10/30),21,22 while apparently ‘silent’ acute DWI
lesions have been noted in up to 25% following
recent stroke, mostly in small studies (e.g. n< 105)
that sought typical stroke symptoms.16,23 Thus, knowl-
edge of the extent of clinical correlates of SVD lesions,
in particular, any ‘red flag’ symptoms or signs that
might highlight lesion worsening, remains limited and
may be being clinically overlooked.
SVD is commonly attributed to traditional vascular
risk factors, particularly hypertension, but also smok-
ing and diabetes, yet these factors only account for 2%
of WMH variance.24 Less is known about potential
contributors such as diet, lifestyle and premorbid
factors.25 Extending the search beyond an individual’s
current clinical status to early and mid-life stages is an
important target for SVD research.26 Understanding
whether combined risk factors have a synergistic
effect on an individual’s risk of developing SVD, as
well as improved recognition of symptoms, would pro-
vide better recognition of persons at risk of SVD devel-
opment or progression, providing insight on whether
multimodal approaches to prevention and treatment
should be taken.
Few studies have comprehensively assessed SVD
lesion progression, symptomatology and wide-ranging
risk factors. Hence we describe the protocol for a
detailed study to assess the role of cerebrovascular dys-
functions in combination, symptoms, and risk factors
including diet, sleep and early life factors, on longitu-




The Mild Stroke Study 3 (MSS-3: ISRCTN 12113543)
is a detailed prospective observational cohort study
with clinical and imaging follow-up which aims to
recruit up to 300 participants. In addition to a scan
at initial stroke diagnosis, the patients undergo a min-
imum of three study scans over a year; in addition,
those with lacunar stroke or moderate-to-severe
WMH are invited for a further one or two visits
between baseline and six months. The baseline assess-
ment occurs within a maximum of threemonths of
index stroke (Table 1). All participants return 6 and
12months, respectively, after the baseline assessment.
Annually, thereafter up to four years, we will invite
participants to continue annual postal or phone
follow-up with another MRI at three years. The
follow-up questionnaire includes recurrent vascular
events, cognition and functional status. MSS-3 benefits
from systems established during the MSS-1 and MSS-2
studies27,28 and commenced in August 2018.
Study population
Adults >18 years old with mild ischaemic stroke with a
modified Rankin scale (mRS) 2 at recruitment pre-
senting to Edinburgh/Lothian stroke services.
Eligibility criteria
We define stroke as described previously:27,28 clinical
lacunar stroke syndrome (50%) and control partici-
pants with non-lacunar ischaemic stroke syndromes
(50%) i.e. partial anterior circulation syndrome or pos-
terior circulation syndrome, with recent infarct visible
on diagnostic MRI or CT scan compatible with the
clinical syndrome, or if no visible infarct, no other
lesion explaining the stroke symptoms. Participants
with non-lacunar stroke form controls, since they
have similar vascular risk factors and follow similar
secondary prevention, accounting for medication
effects on vessel function.
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We exclude participants with MRI contraindica-
tions, major neurological conditions, severe cardiac
and respiratory disease. All participants give written
informed consent. The study was granted ethical
approval by Southeast Scotland Regional Ethics
Committee (reference 18/SS/0044).
Diagnosis
An expert panel of stroke physicians and neuroradiol-
ogists reach final stroke diagnosis by consensus follow-
ing review of presenting symptoms and signs including
motor or sensory deficit, hemianopia, visuospatial dis-
order, ataxia, dysphasia, dysarthria, cerebellar or
brainstem symptoms, supplemented by diagnostic
brain MRI or CT and other relevant investigations,
as previously described.27,28 An experienced neuroradi-
ologist (JMW) assesses all scans for acute ischaemic
lesions including recent small subcortical infarcts,
prior infarcts or haemorrhages, WMH, lacunes, PVS,
microbleeds, siderosis and atrophy, using standardised
validated scales.2,28
Vascular risk factors, past medical history,
medications and incident vascular events
Each participant provides a medical history of diagno-
ses confirmed by a physician, supplemented by hospital
medical records and general practitioner correspon-
dence, following standard definitions, including diabe-
tes mellitus, hypertension, hypercholesterolaemia,
previous stroke or TIA, peripheral vascular disease,
atrial fibrillation, ischaemic heart disease, valvular
defects, heart failure and physician-diagnosed anxiety,
depression or delirium. We record current medications,
cross-checking with electronic medical records.
At follow-up, we record recurrent stroke, TIA and car-
diac events.













Routine blood tests X
Electrocardiogram X
Carotid Doppler ultrasound X
Symptom assessment X X X X
Cognitive tests X X X X
MRI X X X X
Retinal imaging X X X X
Blood pressure X X X X
Recurrent vascular events X X X X
NIHSS X X X X
mRS X X X






24-h blood pressure monitoring X
Premorbid IQ (education, National Adult Reading Test) X
Informant questionnaire: IQCODE, NPI-Q, AES-I X X
Pulse wave measures X
Nine-hole peg test X X
Timed upþ go X X
Stroke Impact Scale X X




MRI: magnetic resonance imaging; NIHSS: National Institute of Health Stroke Scale; IQCODE: Informant Questionnaire for Cognitive Decline in the
Elderly; NPI-Q: Neuropsychiatric Inventory Questionnaire; AES-I: Apathy Evaluation Scale-Informant.
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Subjective symptoms
We use a structured questionnaire to ask open-ended
questions about subjective symptoms experienced
prior to, at the time of, and since index stroke diagnosis
(see online Supplementary Appendix 1). Participants
also answer questions based on previous clinico-
radiological studies regarding symptoms within the
past month including subjective memory concerns,
confusional episodes, unsteadiness, falls, dizziness and
headaches.29
Participants self-administer the Fatigue Severity
Scale,30 Generalized Anxiety Disorder-7,31 the Center
for Epidemiologic Studies-Depression Scale32 and an
adapted Pittsburgh Sleep Quality Index.33
Informant-reported symptoms
A nominated close friend or relative completes the fol-
lowing prior to the baseline visit: Neuropsychiatric
Inventory Questionnaire,34 behavioural changes since
stroke,35 Apathy Evaluation Scale, Informant version36
and the Informant Questionnaire for Cognitive Decline
in the Elderly37 repeated at 12months.
Family, lifestyle, social and early life factors
We record stroke or dementia family history including
age at diagnosis, alcohol consumption and smoking
status including quantity and duration. Participants
self-administer the EPIC-Norfolk Food Frequency
Questionnaire, a comprehensive dietary overview
including salt intake.38,39
To assess early life socioeconomic status, we record
childhood postal address, number of individuals,
rooms and toilets in the property and parental occupa-
tions. We note ethnicity, educational duration and
attainment,40 occupation, current postcode and retire-
ment age.
Physical examination
We record presenting and current neurological deficits
and stroke severity (NIHSS), blood pressure three
times, gait (Timed Up and Go), manual dexterity (9-
Hole Peg Test), height and weight.
Cognitive assessment
Participants complete the comprehensive 30-min neu-
ropsychological test protocol based on the National
Institute of Neurological Disorders and Stroke–
Canadian Stroke Network (NINDS-CSN) Vascular
Cognitive Impairment Harmonization Standards.
This battery spans multiple cognitive domains and
includes the Montreal Cognitive Assessment (MoCA),
Hopkins Verbal Learning Test-revised, Controlled
Oral Word Association Test, Animal Naming, Letter
Digit Coding and Trailmaking Tests AþB.
We estimate peak adult intelligence using the
National Adult Reading Test.40
Participants repeat MoCA and Trailmaking Tests
AþB at each visit. We use three different MoCA ver-
sions, randomly assigning a test sequence to each par-
ticipant to minimise learning effects on serial test
performance.
Functional recovery
We administer the mRS41 at baseline, 6 and 12months
and the Stroke Impact Scale42 at 6 and 12months.
Magnetic resonance imaging
We scan all participants at diagnosis at 1.5 T (General
Electric Signa HDxt) or 3T (Siemens Prisma) MRI or
CT with core structural brain MRI sequences at each
visit: 3D T1w, T2w, fluid attenuated inversion recov-
ery, susceptibility-weighted (SWI/SWAN/GRE) and
single- or multi-shell diffusion imaging (dMRI).
Subsequent full cerebrovascular assessment and all
follow-up imaging are at 3 T.
At one to threemonths post-stroke, participants
undergo 3T MRI to measure BBB integrity, CVR,
cerebral blood flow (CBF) and intracranial vascular
and CSF pulsatility (protocol in online
Supplementary Appendix 2). We assess BBB integrity
using dynamic contrast-enhanced (DCE)-MRI and
gadolinium-based contrast agent (gadobutrol) injec-
tion,11,43 unless eGFR <30ml/min. We assess CVR
using a blood oxygenation level dependent (BOLD)
MRI sequence, during which participants inhale air
with intermittent-added CO2 (12-min paradigm alter-
nating 2min air and 3min 6% CO2) through a tight-
fitting facemask, described previously.13,44 Arterial,
venous and CSF pulsatility are measured using phase
contrast MRI sequences.14,44 We measure CBF using
major arterial phase contrast flow measures obtained
during pulsatility measurements (and arterial spin
labelling where feasible).
We process MRI computationally using well-
validated methods to assess intracranial volume, CSF,
normal-appearing white and grey matter, WMH vol-
umes, index and prior stroke lesion volumes, lacunes,
microbleeds and perivascular space metrics.45,46 We
visually quantify index and prior stroke lesions (loca-
tion, type), WMH (baseline, change), lacunes (number,
location), perivascular spaces, microbleeds, siderosis,
superficial and deep brain volume loss, according to
STRIVE criteria using validated scales.2,47–51 See
online Supplementary Appendix 2 for image processing
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methods description including advanced neuroimaging
data.
Retinal imaging
We assess vision (Logmar cabinet, Sussex Vision) and
use Spectralis OCT2VR with Optical Coherence
Tomography Angiography (OCTA) (Heidelberg
Engineering) at each visit, imaging retinal vessels, ret-
inopathy, nerve fibre layer thickness, choroid OCTA,
intra-retinal and sub-retinal fluid. We computationally
process retinal and arteriolar widths, branching pat-
terns, complexity,52 nerve fibre layer thickness and
microvessels on OCTA using well-validated tools.53
See online Supplementary Appendix 2 for processing
details.
Systemic vascular measures
We record BP at three standard points during the base-
line visit (Omron) and measure arterial velocities
through pulse wave velocity and pulse wave analysis
using a tonometric device (SphygmoCorVR , AtCor
Medical/Vicorder, Skidmore Medical) held over the
carotid and radial pulses while supine. We provide a
24-h ambulatory BP monitoring device (SpaceLabs
Medical) to most and encourage all to submit self-
monitored blood pressure recordings. We repeat BP
measurements at all study visits.
Biochemical, haematological, cardiovascular and
imaging investigations
We document routinely collected index stroke investi-
gation results including serum haematology and bio-
chemistry, electrocardiogram, echocardiography and
carotid Doppler ultrasound. We collect 18ml venous
blood at baseline for inflammatory and endothelial
function markers. We store 20ml urine for inflamma-
tory marker analysis and 5ml for albumin-to-
creatinine ratio.
Endpoints
The primary endpoint is the proportion of SVD lesions
that regress, progress or appear de novo in the year
after stroke. The secondary endpoints are: (a) BBB
integrity; (b) CVR; (c) intracranial vascular/CSF pul-
satility; (d) WMH, PVS, lacunes and microbleeds; (e)
white matter structural integrity measured with diffu-
sion tensor and T1 parameters and (f) incidence of
reported symptoms including neuropsychiatric and
cognitive symptoms, recurrent stroke, transient ischae-
mic attacks and cardiac events.
Statistical analysis
Sample size calculation. In a previous study with one year
of longitudinal imaging follow-up at this centre, 10.6%
of participants had a de novo lesion on MRI at follow-
up.28 In the same study, 65% had a mean 5.5ml
WMH volume increase and 35% had a mean 6.6ml
decrease.54 A sample of 250 participants would be
required to detect WMH change in the year after
stroke, with significance 0.05 and power 0.90 in univar-
iate analysis. We aim to recruit up to total 300 partic-
ipants which allows for loss to follow-up.54
Proposed analyses. In our primary analyses, we will use
linear mixed effects models adjusted for age, vascular
risk factors and baseline SVD burden to estimate the
effect of cerebrovascular structure/function on SVD
lesion progression and regression.
Secondarily, we will use similar models and other
approaches (e.g. stratifying by low vs. high SVD
burden, stroke subtype) to quantify associations of
the following factors with lesion change: cognitive
test scores and incident cognitive impairment; symp-
tom test scores and incident symptoms; functional
status; life course factors; lifestyle factors; blood pres-
sure; systemically measured vascular stiffness; retinal
measures; and inflammatory and endothelial function
markers.
Discussion
The MSS-3 is a detailed prospective observational
study which will advance our knowledge of how
detailed measures of small vessel dysfunction and
changing lesions relate to comprehensive symptom,
cognitive, retinal, early life and lifestyle factors, wheth-
er some individuals are more vulnerable than others to
the effects of small vessel dysfunction and whether a
single candidate measure could best differentiate
abnormal from normal-appearing brain tissue by
stage and severity of SVD.
This study is novel in its concurrent use of advanced
neuroimaging techniques to measure CVR, BBB leak-
age, CBF and vascular/CSF pulsatility: the first time
these measures have been performed contemporane-
ously, alongside an unprecedented comprehensive
assessment of symptoms and signs as they relate to
these measures and lesion changes across multiple
time-points. We build on previous studies,8,55 establish-
ing a well-phenotyped profile of the dynamic natural
history of SVD, capturing this rich dataset in the sub-
acute post-stroke phase, monitoring the vulnerable
brain at risk for early disease accumulation.16,56 Our
systematic approach is a template for application to
future research studies, designed to optimally assess
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rates of disease progression and regression, translatable
to other SVD presentations including mild cognitive
impairment.
This study will fill an existing gap of longitudinal
imaging studies evaluating symptoms such as apathy,
fatigue, anxiety, delirium, sleep disturbance and emo-
tional liability, contributing to the detection of preclin-
ical SVD states. We will identify ‘red flags’ to the
presence and progression of SVD, so that we may inter-
cept disease earlier, even before it develops, rather than
in patients presenting with overt brain dysfunction, e.g.
stroke, dementia. We will gain insight into novel pre-
ventative and therapeutic targets by uncovering the
nature of and factors associated with lesion regression.
This study will deepen our understanding of SVD,
essential to future prevention and treatment of stroke
and vascular dementia.
To date, we have recruited 116 participants. The
baseline visit lasts 6.5 h, and most are willing to
attend three further visits, each lasting two hours,
with positive participant feedback, demonstrating the
feasibility of applying this design at other centres.
Trial registration
ISRCTN 12113543
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